Cerecor

Avalo Therapeutics, Inc. is a biopharmaceutical company. engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II). The company plans to initiate a pivotal trial of CERC-803 in LAD-II (SLC35C1-CDG) by the first half of 2021 and anticipates topline data in the second half of 2021.

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II

ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced a collaboration with The Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) led by Eva Morava-Kozicz, M.D. Ph.D., Principal Investigator of the trial, Professor of Medical Genetics, Senior Associate Consultant, Department of Clinical Genomics, Mayo Clinic and Editor in Chief of the Journal of Inherited Metabolic Disease on a prospective pivotal trial evaluating the safety and efficacy of CERC-801 in patients suffering from Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation (PGM1-CDG).

Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG

On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end

Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update

CTI BioPharma

IVERIC bio Inc

Ligand Pharmaceuticals

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long-term approach to its small number of investments, which are focused on companies that have successfully commercialized products and which are in a strong financial position.

4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)

ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Gilla Kaplan, Ph.D., to the Board of Directors. Dr. Kaplan brings with her over 30 years of academic and industry experience.

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced it has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic. CERC-002 is a first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody currently being developed as a treatment for severe pediatric onset Crohn’s disease as well as in a placebo-controlled proof-of-concept trial evaluating the safety and efficacy in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome (ARDS).

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

The data strongly support Cerecor’s ongoing clinical study of CERC-002 as a novel potential treatment for COVID-19-related ARDS The data strongly support Cerecor’s ongoing clinical study of CERC-002 as a novel potential treatment for COVID-19-related ARDS

Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS

-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement

Cerecor Reports Second Quarter 2020 Financial Results and Business Update

ROCKVILLE, Md., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 8:00 a.m. EDT.

Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation (RPDD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).

Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).

Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations

Top-line Data Anticipated in Fourth Quarter 2020 Top-line Data Anticipated in Fourth Quarter 2020

Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS

ROCKVILLE, Md., June  11, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previously announced underwritten offering of 15,180,000 shares of its common stock (inclusive of 1,980,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of Cerecor’s common stock), at a public offering price of $2.50 per share. Certain insiders, including certain of the Company’s officers, purchased shares of Cerecor common stock in the offering.

Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

ROCKVILLE, Md., June  09, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into an underwriting agreement with Oppenheimer & Co. Inc. under which the underwriter agreed to purchase, on a firm commitment basis, 13,200,000 shares of common stock of the Company, at a public offering price of $2.50 per share (the “Public Offering Price”). The offering is expected to close on or about June 11, 2020, subject to customary closing conditions.

Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock

ROCKVILLE, Md., June  08, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common stock in an underwritten public offering. Cerecor intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover over-allotments in the sales of the shares, if any. All of the shares of common stock will be offered by Cerecor. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cerecor Inc. Announces Proposed Public Offering of Common Stock

-Appoints Sol J. Barer, Ph.D. as Chairman of the Board- Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board

Cerecor Announces Changes to Board of Directors

ROCKVILLE, Md., March  26, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announces that it will explore the role of an inflammatory cytokine, LIGHT, in patients with COVID-19 induced Acute Respiratory Distress. The Company will use its proprietary free LIGHT assay as well as a multiplex assay to determine whether there are differences in LIGHT levels and other inflammatory markers including IL-18 and IFN-g in patients with mild to moderate vs severe disease with Acute Lung Injury / Acute Respiratory Distress Syndrome (“ARDS”).

Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome

ROCKVILLE, Md., March  06, 2020  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Jeff Wilkins, MD  has joined the Company as its Chief Development Officer, with a specific focus on CERC-002, CERC-006 and CERC-007 clinical development programs.

Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer

-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases     -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer

Cerecor and Aevi Genomic Medicine Complete Merger

-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases    -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer    -Strategic Alternatives Being Explored for Neurological Assets and Millipred   ®

Cerecor to Acquire Aevi Genomic Medicine

ROCKVILLE, Md., Nov.  04, 2019  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience, Inc. (“AYTU”) in a deal valued in excess of $43 million including the assumption of various liabilities and product-related obligations. The consideration includes a combination of cash and Aytu preferred stock (the “shares”) totaling $17 million and the assumption of Cerecor’s outstanding payment obligations payable to Deerfield CSF, LLC in the amount of $15 million (“Deerfield Note”) and certain other liabilities in excess of $11 million, providing non-dilutive cash generation for Cerecor. The funds from the transaction, coupled with the removal of the aforementioned short-term obligations, extend the runway toward NDA submission of CERC-801 and its associated Priority Review Voucher (PRV).

Cerecor Closes Deal to Sell Pediatric Portfolio

-Deal Valued in Excess of $32 Million    -Eliminates Debt Associated with Avadel / Deerfield Agreement    -Provides Non-Dilutive Cash Generation to Fund R&D      -Extends Runway Towards NDA Submission of CERC-801

Cerecor To Sell Pediatric Portfolio to AYTU BioScience

Shares of Cerecor Inc. CERC, +2.96% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S.

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

ROCKVILLE, Md., Aug.  21, 2019  (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CERC-802, an ultra-pure, oral formulation of D-mannose currently in development for the treatment of Mannose-Phosphate Isomerase Deficiency, also known as MPI-CDG or CDG-1b.

News for Cerecor Stock (CERC)